Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations.

Questions To Ask Your Health Care Provider

• How do I get genetic testing for a BRCA mutations?
• Does carrying a mutation in BRCA or another gene change your treatment recommendations for me?
• Should I have biomarker testing?
• Which treatment is the best for me?
• Will my insurance pay for Lynparza to treat my pancreatic cancer?
• Is there a clinical trial that I can join?

Open Clinical Trials

The following treatment studies are enrolling people diagnosed with pancreatic cancer.

• NCT07252232: Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304). This study is testing whether a new drug, Daraxonrasib (RMC-6236), helps prevent pancreatic cancer from returning after surgery and chemotherapy.
• NCT07491445: Comparing Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (Rasolute 303). This study is testing a new targeted drug called daraxonrasib to see if it helps people with metastatic pancreatic cancer live longer or keep their cancer from growing longer than standard chemotherapy alone.
• NCT06411691: KRAS-Targeted Vaccine Combined With Targeted Therapy for Patients With Stage IV MMR-p Colorectal Cancer or Pancreatic Ductal Adenocarcinoma. This study will test the efficacy and immune response to a KRAS vaccine combined with immunotherapy for unresectable or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metastatic MMR-p pancreatic ductal adenocarcinoma (PDAC) patients with measurable disease following first-line chemotherapy.
• NCT06782932: Comparing Neoadjuvant/​Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer. The purpose of this study is to determine the  best dose of the drug AGEN2373 that is safe when given in combination with immunotherapy and Pancreatic GVAX vaccine and evaluate the safety and activity of balstilimab and AGEN2373 in combination with different vaccines in surgically resectable pancreatic adenocarcinoma.
• NCT04858334: Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO). This study compares the usual approach (observation) to treatment for one year with olaparib in patients with a BRCA1, BRCA2 or PALB2 mutation.
• NCT05932862: Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors. The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with advanced cancers, including pancreatic cancer. 
• NCT04150042: SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells. This study looks at whether melphalan, BCNU, vitamin B12b and vitamin C followed by autologous (self) bone marrow stem cell infusion is safe and effective for treating patients with advanced pancreatic cancer or stage 4, HER2-negative breast cancer for people with a BRCA1, BRCA2 or PALB2 inherited mutation. 

Other clinical trials for people with pancreatic cancer can be found here.

The following studies look at treatment for people with advanced solid tumors. 

• NCT02264678: Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents. This is a study of orally administered ceralasertib combined with chemotherapy regimens and/or novel anticancer agents for patients with advanced cancer. The study enrolls people with tumors that are HRD-positive or who have inherited mutations in BRCA1, BRCA2, ATM, RAD51C or RAD51D.  
• NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). This research is designed to learn whether treatment with a new PARP inhibitor, AZD5305, used alone or in combination with anti-cancer agents is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors. The study is open to people who have previously been treated with PARP inhibitors.  
• NCT04267939: ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer. This study looks at how well people with advanced solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib. This study is open to people with inherited mutations in ATM, BRCA1, BRCA2 and other genes. Contact the study coordinator for information about eligibility for people with mutations in other genes. 
• NCT04657068: Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors. This study looks at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes that are linked to DNA damage repair. This study is open to people who have an inherited or acquired BRCA or ATM mutation or whose tumors are HRD-positive. This study is open to people whose cancer stopped responding or progressed on PARP inhibitors.